Revcovi | 1709806-75-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Revcovi
• 英文别名: (2S)-2-amino-6-(2-methoxyethoxycarbonylamino)hexanoic acid
• CAS: 1709806-75-6
• 化学式: C₁₀H₂₀N₂O₅
• 分子量: 248.28
• InChiKey: XNGDIOBPVDBNQH-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
  申请人：LEADIANT BIOSCIENCES LTD.

  公开号：US10391154B2

  公开（公告）日：2019-08-27

  Provided are Adenosine Deaminase (ADA), or a polypeptides or peptides having an ADA activity, or an ADA conjugate, pharmaceutical compositions and formulations, products of manufacture and kits, and methods containing them for the prevention and treatment of a scleroderma-associated vasculopathy, in particular proliferative obliterative vasculopathy, progressive obliterative vasculopathy or an idiopathic obliterative vasculopathy and/or preventing or decreasing the progression of scleroderma, wherein optionally the scleroderma comprises a local scleroderma or a diffuse, or a systemic scleroderma.

  本发明提供了腺苷脱氨酶（ADA）或具有ADA活性的多肽或肽类，或ADA共轭物、药物组合物和制剂、制造产品和试剂盒，以及含有它们的用于预防和治疗硬皮病相关性血管病变的方法、特别是增殖性闭塞性血管病变、进行性闭塞性血管病变或特发性闭塞性血管病变和/或预防或减少硬皮病的进展，其中硬皮病可选择包括局部硬皮病或弥漫性或全身性硬皮病。
• COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING FIBROSIS, SYSTEMIC SCLEROSIS AND SCLERODERMA
  申请人：LEADIANT BIOSCIENCES LTD.

  公开号：US20190022196A1

  公开（公告）日：2019-01-24

  Provided are Adenosine Deaminase (ADA), or a polypeptides or peptides having an ADA activity, or an ADA conjugate, pharmaceutical compositions and formulations, products of manufacture and kits, and methods containing them for the prevention and treatment of a scleroderma-associated vasculopathy, in particular proliferative obliterative vasculopathy, progressive obliterative vasculopathy or an idiopathic obliterative vasculopathy and/or preventing or decreasing the progression of scleroderma, wherein optionally the scleroderma comprises a local scleroderma or a diffuse, or a systemic scleroderma.